Kocefan (Ceftriaxone Disodium Salt Hemiheptahydrate)

Ceftriaxone belongs to the cephalosporin class and works by binding to penicillin‑binding proteins on bacterial cell walls. This inhibits the final step of peptidoglycan cross‑linking, weakening the wall and causing bacterial lysis. Its broad spectrum covers many Gram‑negative and some Gram‑positive bacteria.

The dose of Kocefan is determined by the prescribing clinician based on the type and severity of infection, patient weight, age, renal and hepatic function, and local susceptibility patterns. No fixed regimen is provided here; the prescriber tailors the dosage to each individual case.

Ceftriaxone is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy or lactation when the expected benefit justifies any potential risk, and the decision should be made by the treating physician.

To order Kocefan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Both Kocefan (ceftriaxone) and cefotaxime are third‑generation cephalosporins, but ceftriaxone has a longer half‑life, allowing once‑daily dosing, whereas cefotaxime typically requires multiple daily doses. Ceftriaxone also has higher protein binding and broader activity against certain Gram‑negative organisms, making it convenient for outpatient parenteral therapy.

Kocefan should be stored at 2 °C to 8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Maintaining the cold chain preserves drug stability and potency.

Kocefan is supplied as an injectable solution for intravenous administration. It is typically reconstituted with a compatible diluent and infused over a specified period, often as a single daily dose. Administration must be performed by qualified healthcare personnel following aseptic technique and institutional protocols.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, biliary sludging or gallbladder pseudolithiasis, and hemolytic anemia in patients with G6PD deficiency. Prompt recognition and discontinuation are essential if any of these events occur.

Kocefan should be avoided in patients with a known hypersensitivity to ceftriaxone or other cephalosporins. Neonates (≤28 days) receiving calcium‑containing IV solutions should not be given ceftriaxone due to the risk of precipitation. Caution is also advised for patients with severe renal or hepatic impairment, and those with a history of severe allergic reactions.